Ok, I stand corrected. I missed this part of the
Post# of 148112
"Cytodyn disclosed in an investment community conference call that they requested an EUA from FDA for leronlimab for mild to moderate COVID-19 based on data from the Phase 2 CD10 study."
So, the authors just went with that and didn't follow up. Bummer, but great article nonetheless.